(NASDAQ: FOLD) Amicus Therapeutics's forecast annual revenue growth rate of 14.77% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 222.19%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.97%.
Amicus Therapeutics's revenue in 2025 is $571,160,000.On average, 3 Wall Street analysts forecast FOLD's revenue for 2025 to be $192,399,318,378, with the lowest FOLD revenue forecast at $191,661,393,317, and the highest FOLD revenue forecast at $193,158,203,717. On average, 5 Wall Street analysts forecast FOLD's revenue for 2026 to be $232,547,496,842, with the lowest FOLD revenue forecast at $229,021,854,882, and the highest FOLD revenue forecast at $236,512,071,670.
In 2027, FOLD is forecast to generate $270,539,540,884 in revenue, with the lowest revenue forecast at $264,161,143,518 and the highest revenue forecast at $278,133,634,341.